Literature DB >> 18452120

Artificial and bioartificial liver support.

Travis J McKenzie1, Joseph B Lillegard, Scott L Nyberg.   

Abstract

Acute liver failure (ALF) is a widespread problem with an unfavorable prognosis. Currently, liver transplantation is the only direct means of treatment for patients in ALF. Due to the scarcity of donor organs, liver support technologies are being developed and clinically tested with the intent of supporting a patient in ALF until the patient regains native liver function or until a donor organ becomes available. Two major categories of devices are currently being tested. Artificial liver support is purely mechanical, including albumin dialysis. Bioartificial devices contain cellular material. No single system has reproducibly demonstrated improvement in patient mortality. However, with the advent of new technology and cell acquisition techniques, further randomized controlled trials will be necessary to determine the role of artificial and bioartificial liver support devices in the treatment of patients with ALF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452120     DOI: 10.1055/s-2008-1073120

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  22 in total

Review 1.  Cell therapies for liver diseases.

Authors:  Yue Yu; James E Fisher; Joseph B Lillegard; Brian Rodysill; Bruce Amiot; Scott L Nyberg
Journal:  Liver Transpl       Date:  2012-01       Impact factor: 5.799

Review 2.  Biology of the adult hepatic progenitor cell: "ghosts in the machine".

Authors:  Houda Darwiche; Bryon E Petersen
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

3.  Gene transfer of c-met confers protection against D-galactosamine/lipopolysaccharide-induced acute liver failure.

Authors:  Chuanlong Zhu; Yuwen Li; Wenting Li; Quan Wu; Rentao Gao
Journal:  Dig Dis Sci       Date:  2012-01-24       Impact factor: 3.199

4.  Fluidized-bed bioartificial liver assist devices (BLADs) based on microencapsulated primary porcine hepatocytes have risk of porcine endogenous retroviruses transmission.

Authors:  Qian Yang; Fei Liu; Xiao Ping Pan; Guoliang Lv; Anye Zhang; Chen Bo Yu; Lanjuan Li
Journal:  Hepatol Int       Date:  2010-08-15       Impact factor: 6.047

5.  Hepatic assist devices: will they ever be successful?

Authors:  Norman L Sussman; Brendan M McGuire; James H Kelly
Journal:  Curr Gastroenterol Rep       Date:  2009-02

6.  Influence of chitosan nanofiber scaffold on porcine endogenous retroviral expression and infectivity in pig hepatocytes.

Authors:  Bing Han; Xiao-Lei Shi; Jiang-Qiang Xiao; Yue Zhang; Xue-Hui Chu; Jin-Yang Gu; Jia-Jun Tan; Zhong-Ze Gu; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

Review 7.  Neurological management of fulminant hepatic failure.

Authors:  Jennifer A Frontera; Thomas Kalb
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

8.  A new treatment strategy for acute liver failure.

Authors:  Kazuhiro Kotoh; Masaki Kato; Motoyuki Kohjima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Hepatol       Date:  2010-11-27

Review 9.  Cellular therapy for liver disease.

Authors:  Robert C Huebert; Jorge Rakela
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

10.  Engineering analysis and development of the spheroid reservoir bioartificial liver.

Authors:  Malcolm B McIntosh; Stephen M Corner; Bruce P Amiot; Scott L Nyberg
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.